Xencor (NASDAQ:XNCR) Shares Break Above Fifty Day Moving Average – Should You Sell?

Xencor, Inc. (NASDAQ:XNCR)’s stock price passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $25.42 and traded as high as $33.60. Xencor shares last traded at $29.18, with a volume of 8,896,092 shares.

Trending Headlines about Xencor

Here are the key news stories impacting Xencor this week:

• Positive Sentiment: Updated Phase 1 data showed a 45.5% response rate in the kidney-cancer study, with reports describing the treatment’s antitumor activity as “impressive,” “profound,” or “unprecedented.” The results substantially improved investor expectations for XmAb819’s commercial potential. Xencor Shares Rise Pre-Bell After Kidney Cancer Trial Shows 45.5% Response Rate
• Positive Sentiment: Xencor selected a Phase 1 dose and said it plans to advance XmAb819 into a late-stage trial, providing a clearer development path for the program. Xencor Presents Phase 1 Dose Selection Data for XmAb819
• Positive Sentiment: Analyst commentary highlighted the possibility of an FDA accelerated-approval pathway if subsequent studies confirm the early efficacy signal, adding to the bullish sentiment around XNCR. Xencor Strong Buy Potential for FDA Accelerated Approval Pathway
• Neutral Sentiment: The results are from an early-stage study, so the response rate will need validation in larger, later-stage trials. Xencor remains a clinical-stage company with substantial development and regulatory risk.
• Neutral Sentiment: A reported October short-interest figure of zero shares implies no measurable short-covering catalyst, although the data appears inconsistent with the claim of a significant increase in short interest.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Wedbush reiterated an “outperform” rating and issued a $30.00 price objective on shares of Xencor in a report on Wednesday, October 21st. Barclays set a $45.00 target price on Xencor and gave the company an “overweight” rating in a research note on Monday. Raymond James Financial raised their target price on Xencor from $40.00 to $46.00 and gave the stock a “strong-buy” rating in a report on Tuesday, September 1st. JPMorgan Chase & Co. boosted their target price on Xencor from $14.00 to $21.00 and gave the stock a “neutral” rating in a research report on Thursday, September 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a research note on Monday, September 21st. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $35.11.

Xencor Price Performance

The company’s 50 day simple moving average is $25.42 and its 200 day simple moving average is $16.66. The stock has a market cap of $2.17 billion, a P/E ratio of -13.45 and a beta of 0.89.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.51. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The company had revenue of $51.22 million for the quarter, compared to analysts’ expectations of $18.89 million. During the same period last year, the firm posted ($0.41) earnings per share. The business’s quarterly revenue was up 17.4% compared to the same quarter last year. On average, equities research analysts predict that Xencor, Inc. will post -3.05 earnings per share for the current year.

Institutional Trading of Xencor

Several hedge funds have recently added to or reduced their stakes in the business. Seven Fleet Capital Management LP bought a new position in Xencor during the second quarter worth about $7,828,524,000. BlackRock Inc. acquired a new position in Xencor in the second quarter valued at about $219,785,000. Primecap Management Co. CA acquired a new position in Xencor in the second quarter valued at about $163,919,000. Legal & General Group Plc bought a new stake in shares of Xencor in the second quarter worth about $17,568,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Xencor by 3.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,294,887 shares of the biopharmaceutical company’s stock worth $15,613,000 after acquiring an additional 45,599 shares in the last quarter.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California. Founded in 1997, the company develops engineered antibodies and other biologic medicines for the treatment of cancer, autoimmune disorders and other serious diseases.

Xencor’s research is centered on its XmAb technology platform, which is designed to modify antibodies to improve their therapeutic properties or create new antibody-based mechanisms. The platform supports the development of bispecific antibodies, immune-cell engagers and antibodies with extended activity in the body.